Catalent, Inc. (NYSE:CTLT) Receives $55.65 Average Target Price from Analysts

Catalent, Inc. (NYSE:CTLT) has received a consensus rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $55.65.

Several equities analysts have weighed in on CTLT shares. Stephens reaffirmed an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com initiated coverage on Catalent in a research note on Monday. They issued a “sell” rating for the company.

Insiders Place Their Bets

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of large investors have recently added to or reduced their stakes in CTLT. Vanguard Group Inc. lifted its holdings in shares of Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after buying an additional 365,648 shares during the last quarter. Tran Capital Management L.P. lifted its holdings in shares of Catalent by 12.2% during the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after buying an additional 39,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Catalent by 29.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock worth $73,655,000 after buying an additional 376,931 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the last quarter. Finally, UBS Group AG lifted its holdings in shares of Catalent by 2.6% during the fourth quarter. UBS Group AG now owns 726,563 shares of the company’s stock worth $32,644,000 after buying an additional 18,752 shares during the last quarter.

Catalent Price Performance

NYSE CTLT opened at $57.30 on Friday. The stock’s 50-day moving average price is $55.66 and its two-hundred day moving average price is $54.64. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The company has a market cap of $10.37 billion, a PE ratio of -9.39, a PEG ratio of 2.34 and a beta of 1.16. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. On average, analysts predict that Catalent will post -0.17 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.